Advertisement

Significance and relevance of serum preS1 antigen detection in wild-type and variant hepatitis B virus (HBV) infections

  • Marie-Anne Petit
  • F. Capel
  • G. Gerken
  • S. Dubanchet
  • C. Bréchot
  • C. Trépo
Conference paper
Part of the Archives of Virology Supplementum book series (ARCHIVES SUPPL, volume 8)

Summary

These studies assessed whether the serum expression of preS1 antigen could be a useful HBV marker for monitoring the progress of antiviral therapy in the treatment of chronic active hepatitis B (CAH-B) virus infections. Our findings indicate that: 1) the rearrangements we observed in the preS region of mutated HBV DNA molecules during chronic infection did not effect the preS1 sequence (21–47) critical for HBV infectivity; 2) the persistence or even the rebound of preS1 antigen expression during follow-up in responders to antiviral therapy may indicate virus persistence, suggesting the possibility of relapse through wild-type HBV or the emergence of HBV variants following the immunoelimination phase.

Keywords

Antiviral Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Petit MA, Dubanchet S, Capel F (1989) A monoclonal antibody specific for the hepatocyte receptor binding site on hepatitis B virus. Mol Immunol 26: 531–537PubMedCrossRefGoogle Scholar
  2. 2.
    Petit MA, Strick N, Dubanchet S, Capel F, Neurath AR (1991) Inhibitory activity of monoclonal antibody F35.25 on the interaction between hepatocytes (HepG2 cells) and preSl-specific ligands. Mol Immunol 28: 517–521PubMedCrossRefGoogle Scholar
  3. 3.
    Petit MA, Capel F, Dubanchet S, Mabit H (1992) PreSl-specific binding proteins as potential receptors for hepatitis B virus in human hepatocytes. Virology 187: 211–222PubMedCrossRefGoogle Scholar
  4. 4.
    Petit MA, Zoulim F, Capel F, Dubanchet S, Dauguet C, Trepo C (1990) Variable expression of preSl antigen in serum during chronic hepatitis B virus infection: an accurate marker for the level of hepatitis B virus replication. Hepatology 11: 809–814PubMedCrossRefGoogle Scholar
  5. 5.
    Petit MA, Capel F, Zoulim F, Dubanchet S, Chemin I, Penna A, Ferrari C, Trepo C (1992) PreS antigen expression and anti-preS response in hepatitis B virus infections: relationship to serum HBV DNA, intrahepatic HBcAg, liver damage and specific T-cell response. Arch Virol [Suppl] 4: 105–112Google Scholar
  6. 6.
    Brunetto MR, Giarin M, Oliveri F, Saracco G, Barbera C, Parrella T, Abate ML, Chiaberge L, Calvo PL, Manzini P, Verme G, Bonino F (1991) “e” Antigen defective hepatitis B virus and course of chronic infection. J Hepatol [Suppl] 13: S82–S86Google Scholar
  7. 7.
    Gerken G, Kremsdorf D, Capel F, Petit MA, Dauguet C, Manns MP, Meyer Zum Buschenfelde KH, Bréchot C (1991) Hepatitis B defective virus with rearrangements in the preS gene during chronic HBV infection. Virology 183: 555–565PubMedCrossRefGoogle Scholar
  8. 8.
    Tran A, Kremsdorf D, Capel F, Housset C, Dauguet C, Petit MA, Bréchot C (1991) Emergence of and takeover by hepatitis B virus ( HBV) with rearrangements in the preS/S and preC/C genes during chronic HBV infection. J Virol 65: 3566–3574PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • Marie-Anne Petit
    • 1
  • F. Capel
    • 1
  • G. Gerken
    • 2
  • S. Dubanchet
    • 1
  • C. Bréchot
    • 3
  • C. Trépo
    • 4
  1. 1.Immunopathology and Viral ImmunologyINSERM Unité 131ClamartFrance
  2. 2.Medizinische Klinik und PoliklinikJohannes Gutenberg-UniversitätMainzFederal Republic of Germany
  3. 3.CHU NeckerINSERM U 75Paris CedexFrance
  4. 4.INSERM U 271LyonFrance

Personalised recommendations